These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30650962)

  • 1. Directional atherectomy with antirestenotic therapy for the treatment of no-stenting zones.
    Sauguet A; Philippart R; Honton B
    J Cardiovasc Surg (Torino); 2019 Apr; 60(2):198-204. PubMed ID: 30650962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
    Stavroulakis K; Schwindt A; Torsello G; Stachmann A; Hericks C; Bosiers MJ; Beropoulis E; Stahlhoff S; Bisdas T
    J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease.
    Stavroulakis K; Schwindt A; Torsello G; Beropoulis E; Stachmann A; Hericks C; Bollenberg L; Bisdas T
    J Endovasc Ther; 2018 Feb; 25(1):92-99. PubMed ID: 29251204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
    Zeller T; Langhoff R; Rocha-Singh KJ; Jaff MR; Blessing E; Amann-Vesti B; Krzanowski M; Peeters P; Scheinert D; Torsello G; Sixt S; Tepe G;
    Circ Cardiovasc Interv; 2017 Sep; 10(9):e004848. PubMed ID: 28916599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
    Herten M; Torsello GB; Schönefeld E; Stahlhoff S
    Vasc Health Risk Manag; 2016; 12():341-56. PubMed ID: 27621646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
    Giannopoulos S; Kokkinidis DG; Jawaid O; Behan S; Hossain P; Alvandi B; Foley TR; Singh GD; Waldo SW; Armstrong EJ
    Cardiovasc Revasc Med; 2020 Jun; 21(6):771-778. PubMed ID: 31761634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optical coherence tomography guided directional atherectomy with antirestenotic therapy for femoropopliteal arterial disease.
    Stavroulakis K; Bisdas T; Torsello G; Argyriou A; Bollenberg L; Schwindt A
    J Cardiovasc Surg (Torino); 2019 Apr; 60(2):191-197. PubMed ID: 30665284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE).
    Shammas NW; Shammas GA; Jones-Miller S; Shammas WJ; Bou-Dargham B; Shammas AN; Banerjee S; Rachwan RJ; Daher GE
    Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):771-777. PubMed ID: 30420096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
    J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midterm Outcome of Directional Atherectomy Combined with Drug-Coated Balloon Angioplasty Versus Drug-Coated Balloon Angioplasty Alone for Femoropopliteal Arteriosclerosis Obliterans.
    Cai Z; Guo L; Qi L; Cui S; Tong Z; Guo J; Wang Z; Gu Y
    Ann Vasc Surg; 2020 Apr; 64():181-187. PubMed ID: 31449956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results.
    Cioppa A; Stabile E; Popusoi G; Salemme L; Cota L; Pucciarelli A; Ambrosini V; Sorropago G; Tesorio T; Agresta A; Biamino G; Rubino P
    Cardiovasc Revasc Med; 2012; 13(4):219-23. PubMed ID: 22632996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries.
    Sixt S; Carpio Cancino OG; Treszl A; Beschorner U; Macharzina R; Rastan A; Krankenberg H; Neumann FJ; Zeller T
    J Vasc Surg; 2013 Sep; 58(3):682-6. PubMed ID: 23755977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
    Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adjunctive drug-coated balloon therapy in endovascular treatment of common femoral artery disease.
    Imran HM; Hyder ON; Soukas PA
    Cardiovasc Revasc Med; 2019 Mar; 20(3):210-214. PubMed ID: 29970328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherectomy plus antirestenotic therapy for SFA lesions: evolving evidence for better patency rates in complex lesions.
    Lichtenberg M; Korosoglou G
    J Cardiovasc Surg (Torino); 2019 Apr; 60(2):205-211. PubMed ID: 30650960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease.
    Foley TR; Cotter RP; Kokkinidis DG; Nguyen DD; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2017 May; 89(6):1078-1085. PubMed ID: 28295971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study.
    Rocha-Singh KJ; Sachar R; DeRubertis BG; Nolte-Ernsting CCA; Winscott JG; Krishnan P; Scott EC; Garcia LA; Baeriswyl JL; Ansel G; Rosenfield K; Zeller T;
    Catheter Cardiovasc Interv; 2021 Sep; 98(3):549-558. PubMed ID: 34080792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-Year Outcomes of Orbital Atherectomy Combined With Drug-Coated Balloon Angioplasty for Treatment of Heavily Calcified Femoropopliteal Lesions.
    Kokkinidis DG; Jawaid O; Cantu D; Martinsen BJ; Igyarto Z; Valle JA; Waldo SW; Armstrong EJ
    J Endovasc Ther; 2020 Jun; 27(3):492-501. PubMed ID: 32364000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.